Evaluation of the safety and antiviral efficacy of the tenofovir alafenamide fumarate molecule in immunosuppressed patients

Authors : Serdar DURAK, Arif Mansur COŞAR

Pages : 1688-1692

Doi:10.32322/jhsm.1179106

View : 43 | Download : 12

Publication Date : 2022-10-25

Article Type : Research Paper

Abstract :Aim: Patients with chronic or prior hepatitis B virus insert ignore into journalissuearticles values(HBV); infection may experience HBV reactivation during immunosuppressive therapy. The objective of this study was to evaluate the safety and antiviral efficacy of tenofovir alafenamide fumarate insert ignore into journalissuearticles values(TAF); for prophylaxis of HBV reactivation in patients on immunosuppressive therapy. Material and Method: This study included patients who were started on immunosuppressive treatment due to hematologic/solid malignancy, autoimmune disease, or inflammatory disease and were treated with TAF for at least six months due to HBsAg and/or total anti-HBc positivity at Karadeniz Technical University Farabi Hospital between January 2018 and February 2021. Electronic medical records were retrospectively reviewed and the adverse event profile was analyzed. Results: Of the 94 patients enrolled in the study, 70.2% insert ignore into journalissuearticles values(n=66); were male. The mean age of the patients was 60.37±14.56 years. The reasons for initiation of immunosuppressive drug treatment were hematologic malignancies in 48.9% insert ignore into journalissuearticles values(n=46);, solid tumors in 27.7% insert ignore into journalissuearticles values(n=26);, and other causes insert ignore into journalissuearticles values(autoimmune/inflammatory); in 23.4% insert ignore into journalissuearticles values(n=22);. There was no statistically significant difference in creatinine, phosphorus, glucose, and LDL profile between baseline and 6-12 months of TAF treatment insert ignore into journalissuearticles values(p=0.861, p=0.136, p=0.323, p=0.304, respectively);. All patients in whom HBV DNA was detectable at baseline became negative at the last follow-up visit. None of the patients developed HBV reactivation and there was no need to discontinue antiviral/immunosuppressive treatment due to side effects. Conclusion: TAF is a safe and effective short-term option to prevent HBV reactivation in patients receiving immunosuppressive therapy.
Keywords : Hepatitis B, chronic hepatitis B, reactivation, tenofovir alafenamide, chemotherapy, immunosuppression

ORIGINAL ARTICLE URL